Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Clinical trial NCT04592237 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04592237
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Aggressive Variant Prostate Carcinoma Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Metastatic Prostate Neuroendocrine Carcinoma Metastatic Prostate Small Cell Carcinoma Stage IV Prostate Cancer AJCC v8

Start date: 2020-12-29
Primary completion: 2027-12-31
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.